4.7 Article

Disease severity and proton pump inhibitor use impact strongest on faecal microbiome composition in liver cirrhosis

期刊

LIVER INTERNATIONAL
卷 40, 期 4, 页码 866-877

出版社

WILEY
DOI: 10.1111/liv.14382

关键词

aetiology; cirrhosis; disease severity; inflammation; malnutrition; proton pump inhibitor

资金

  1. Austrian Science Fund (FWF) [P 24362]
  2. Center for Biomarker Research in Medicine (CBmed)
  3. COMET K1 center - Austrian Research Promotion Agency
  4. Collaborative Research Centre 992 Medical Epigenetics (DFG) [SFB 992/1 2012]
  5. German Federal Ministry of Education and Research [BMBF] [031 A538A/A538C RBC, 031L0101B/031L0101C de. NBI-epi, 031L0106 de. STAIR]

向作者/读者索取更多资源

Background & Aims Compositional changes of the faecal microbiome in cirrhosis are well described and have been associated with complications and prognosis. However, it is less well known, which disease or treatment-related factors affect microbiome composition most distinctively. Methods 16S rDNA sequencing data of 88 cirrhotic outpatients were investigated. Factors influencing microbiome composition were analysed by univariate and multivariate redundancy analysis. The association of the identified factors with changes in diversity and taxonomic composition was studied in depth using analysis of composition of microbiome, LDA-effect size and least absolute shrinkage and selection operator regularized regression. Results Disease severity and aetiology, proton pump inhibitor (PPI) use, nutritional status, age and C-reactive protein are significant explanatory variables for faecal microbiome composition in liver cirrhosis. Despite some taxonomic overlaps especially between disease severity and PPI use, we could show that the effects of disease severity, aetiology, PPI use and age are independent factors influencing microbiome composition also in subgroup analyses. Conclusion Our cross sectional system biology study identifies disease severity, aetiology, PPI use and age as independent factors that influence microbiome composition in liver cirrhosis. In chronic diseases with high morbidity, such as liver cirrhosis, precise patient metadata documentation is of utmost importance in microbiome analysis. Further studies with a higher sample size are necessary to validate this finding. Trial Registration Number: NCT01607528

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据